Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986141 · 5 trials · 5 indications
The change from baseline in thrombus area post-treatment with BMS-986141 versus pretreatment. Baseline is defined as the last non-missing result (including repeated and unscheduled assessments) with a collection date-time less than the datetime of study medication.
The incidence of a composite of symptomatic ischemic stroke by Day 28 and unrecognized brain infarction assessed by MRI at Day 28 was to be reported by arm in all treated participants.
The percentage of participants with composite of major bleeding and CRNM bleeding was to be reported. Point estimates and 95% CIs for event rates were to be presented by treatment, together with point estimates and 95% CIs for the difference of event rates between each BMS-986141 arm and placebo.
Serious adverse event (SAE) Adverse event (AE) Electrocardiogram (ECG)
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1: Ticagrelor + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 2: Aspirin + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 4: BMS-986141 | EXPERIMENTAL | - |
| BMS-986141 0.8mg | EXPERIMENTAL | BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets) |
| BMS-986141 4.8mg | EXPERIMENTAL | BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets) |
| Placebo | PLACEBO_COMPARATOR | Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets) |
| BMS 986141 and Rifampin | EXPERIMENTAL | - |
| BMS-986141 and Dilitazem | EXPERIMENTAL | - |
| Part A Panel 1: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 2: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 3: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 4: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 5: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 6: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo single dose by mouth as specified |
| Part A Panel 7: BMS-986141 | EXPERIMENTAL | Single dose by mouth as specified |
| Part A Panel 8: BMS-986141 | EXPERIMENTAL | Single dose by mouth as specified |
| Part B Panel 1: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part B Panel 2: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part B Panel 3: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part C Panel 1: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part C Panel 2: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part C Panel 3: BMS-986141 or Placebo | EXPERIMENTAL | BMS-986141 or Placebo by mouth as specified |
| Part D Panel 1: BMS-986141 and Aspirin | EXPERIMENTAL | BMS-986141 and Aspirin by mouth as specified |
| Part D Panel 1: Placebo matching BMS-986141 and Aspirin | PLACEBO_COMPARATOR | BMS-986141 placebo and Aspirin by mouth as specified |
| Part E Panel 1: BMS-986141 and Itraconazole | EXPERIMENTAL | BMS-986141 and Itraconazole by mouth as specified |
| Name | Type | Description |
|---|---|---|
| Ticagrelor | DRUG | Specified dose on specified days |
| BMS-986141 | DRUG | Specified dose on specified days |
| Aspirin | DRUG | Specified dose on specified days |
| Placebo | OTHER | - |
| BMS 986141 | DRUG | Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22) |
| Rifampin | DRUG | Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22) |
| Dilitazem | DRUG | Single dose BMS-986141 and Multiple doses of Dilitazem |
| Itraconazole | DRUG | - |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: * Male or female between 18 to 75 years of age, inclusive, and body mass index (weight kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 1...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
BMS-986141 is an investigational small molecule developed by Bristol-Myers Squibb Company (NYSE: BMY) for atherothrombotic diseases, including coronary artery disease, ischemic stroke, and thrombosis. It is a protease activated receptor-4 antagonist being studied to reduce the chances of additional strokes or mini strokes.
BMS-986141 targets F2RL3, also known as protease activated receptor-4 (PAR-4). It acts as an antagonist at this receptor. The compound is a small molecule designed to inhibit PAR-4 mediated platelet activation, which is being explored in the setting of thrombosis and atherothrombotic disease.
BMS-986141 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the clinical studies evaluating the compound in thrombosis-related conditions.
BMS-986141 is in Phase 1 development and is investigational. It has not been approved by the FDA. Completed studies include Phase 1 pharmacokinetic trials and Phase 2 studies in coronary artery disease and thrombosis, with no active trials currently listed.
BMS-986141 has been studied in completed trials including NCT05093790, which evaluated it added on to aspirin or ticagrelor in stable coronary artery disease; NCT02957448, a rifampin drug interaction study; NCT02922452, a diltiazem pharmacokinetic study; and NCT02671461, a Phase 2 study in thrombosis.
Yes, BMS-986141 and BMS 986141 refer to the same investigational compound. The difference is only in punctuation, with the hyphenated form used in the drug name and the spaced form appearing as an alternative name in study records and literature.